Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Abstract

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).